Vickie Zhang

2.7k total citations
16 papers, 357 citations indexed

About

Vickie Zhang is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Vickie Zhang has authored 16 papers receiving a total of 357 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Hematology, 5 papers in Genetics and 4 papers in Molecular Biology. Recurrent topics in Vickie Zhang's work include Acute Myeloid Leukemia Research (10 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (5 papers) and Advanced NMR Techniques and Applications (3 papers). Vickie Zhang is often cited by papers focused on Acute Myeloid Leukemia Research (10 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (5 papers) and Advanced NMR Techniques and Applications (3 papers). Vickie Zhang collaborates with scholars based in United States, France and United Kingdom. Vickie Zhang's co-authors include Robert Bok, Daniel B. Vigneron, John Kurhanewicz, Ralph E. Hurd, Albert P. Chen, Sarah J. Nelson, Matthew L. Zierhut, Ilwoo Park, Mark J. Albers and Yi‐Fen Yen and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Vickie Zhang

16 papers receiving 349 citations

Peers

Countries citing papers authored by Vickie Zhang

Since Specialization

Citations

This map shows the geographic impact of Vickie Zhang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vickie Zhang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vickie Zhang more than expected).

Fields of papers citing papers by Vickie Zhang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vickie Zhang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vickie Zhang. The network helps show where Vickie Zhang may publish in the future.

Co-authorship network of co-authors of Vickie Zhang

This figure shows the co-authorship network connecting the top 25 collaborators of Vickie Zhang. A scholar is included among the top collaborators of Vickie Zhang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vickie Zhang. Vickie Zhang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Recent Use of Pediatric Extrapolation in Pediatric Drug Development in US 2023 ·Journal of Biopharmaceutical Statistics ·Jingjing Ye, Vickie Zhang, Foteini Strimenopoulou, (unknown), Haitao Pan, Mayadah Shabbout, Margaret Gamalo	5
2	AGILE: A Global, Randomized, Double-Blind, Phase 3 Study of Ivosidenib + Azacitidine Versus Placebo + Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation 2021 ·Blood ·Pau Montesinos, Christian Récher, Susana Vives, Ewa Zarzycka, Jianxiang Wang, Giambattista Bertani, Michael Heuser, Rodrigo T. Calado, Andre C. Schuh, Su‐Peng Yeh, Scott R. Daigle, Jianan Hui, Vickie Zhang, Shuchi S. Pandya, Diego A. Gianolio, Stéphane de Botton, Hartmut Döhner	7
3	Statistical considerations in clinical trial design with event‐free survival as the primary efficacy endpoint 2021 ·Pharmaceutical Statistics ·Tu Xu, Yiming Zhang, Meredith A. Goldwasser, Vickie Zhang	1
4	Simultaneous Metabolic and Perfusion Imaging Using Hyperpolarized 13C MRI Can Evaluate Early and Dose-Dependent Response to Radiation Therapy in a Prostate Cancer Mouse Model 2020 ·International Journal of Radiation OncologyBiologyPhysics ·Hecong Qin, Vickie Zhang, Robert Bok, Romelyn Delos Santos, J. Adam M. Cunha, I‐Chow Hsu, (unknown), (unknown), Subramaniam Sukumar, Peder E. Z. Larson, Daniel B. Vigneron, David M. Wilson, Renuka Sriram, John Kurhanewicz	17
5	Molecular Mechanisms Mediating Relapse Following Ivosidenib Monotherapy in Patients with IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia 2019 ·Blood ·Sung Choe, Hongfang Wang, Courtney D. DiNardo, Eytan M. Stein, Stéphane de Botton, Amir T. Fathi, Martin S. Tallman, Hagop M. Kantarjian, Richard M. Stone, Lynn Quek, Zenon Konteatis, Lenny Dang, Vickie Zhang, Hua Liu, Eyal C. Attar, Bin Wu	4
6	High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib (AG-120) and Azacitidine 2019 ·Blood ·Scott R. Daigle, Sung Choe, Lynn Quek, Courtney D. DiNardo, Anthony S. Stein, Eytan M. Stein, Amir T. Fathi, Olga Frankfurt, Andre C. Schuh, Hagop M. Kantarjian, Vickie Zhang, Thomas Winkler, Paresh Vyas, Bin Wu	10
7	Complex Polyclonal Resistance Mechanisms to Ivosidenib Monotherapy in IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia Revealed By Single Cell Sequencing Analyses 2019 ·Blood ·Hongfang Wang, Sung Choe, Courtney D. DiNardo, Eytan M. Stein, Stéphane de Botton, Amir T. Fathi, Martin S. Tallman, Hagop M. Kantarjian, Richard M. Stone, Lynn Quek, Vickie Zhang, Hua Liu, Eyal C. Attar, Bin Wu	2
8	AGILE: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Ivosidenib in Combination with Azacitidine in Adult Patients with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation 2019 ·Blood ·(unknown), Christian Récher, Vadim Doronin, Rodrigo T. Calado, Jun Ho Jang, Yasushi Miyazaki, Jianxiang Wang, Diego A. Gianolio, Scott R. Daigle, Thomas Winkler, Vickie Zhang, Peter Paschka	9
9	Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia (ND AML). 2019 ·Journal of Clinical Oncology ·Courtney D. DiNardo, Anthony S. Stein, Eytan M. Stein, Amir T. Fathi, Olga Frankfurt, Andre C. Schuh, Giovanni Martinelli, Prapti A. Patel, Emmanuel Raffoux, Peter Tan, Amer M. Zeidan, Stéphane de Botton, Hagop M. Kantarjian, Richard M. Stone, Du Lam, Jing Gong, Vickie Zhang, Thomas Winkler, Bin Wu, Paresh Vyas	21
10	AGILE: A phase 3, multicenter, randomized, placebo-controlled study of ivosidenib in combination with azacitidine in adult patients with previously untreated acute myeloid leukemia with an IDH1 mutation. 2018 ·Journal of Clinical Oncology ·Eytan M. Stein, Courtney D. DiNardo, Jun Ho Jang, Yasushi Miyazaki, (unknown), (unknown), Vickie Zhang, Daniel O. Koralek, Bin Wu	9
11	Genetic Profiling and Deep IDH1 Mutation Clearance to ≤0.04% in Ivosidenib (AG-120)-Treated Patients with Mutant IDH1 Relapsed or Refractory and Untreated AML 2017 ·Blood ·Richard M. Stone, Sung Choe, Vickie Zhang, Benoît Marteyn, Virginie Penard‐Lacronique, Hongfang Wang, Courtney D. DiNardo, Eytan M. Stein, Amir T. Fathi, Martin S. Tallman, Hagop M. Kantarjian, Eyal C. Attar, Bin Wu, Stéphane de Botton	1
12	Ivosidenib or Enasidenib Combined with Standard Induction Chemotherapy Is Well Tolerated and Active in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation: Initial Results from a Phase 1 Trial 2017 ·Blood ·Eytan M. Stein, Courtney D. DiNardo, Alice S. Mims, Michael R. Savona, Keith W. Pratz, Anthony S. Stein, Amir T. Fathi, Richard M. Stone, Daniel A. Pollyea, Olatoyosi Odenike, Bob Löwenberg, Hartmut Döhner, Gary J. Schiller, Ira Gupta, Salah Nabhan, Vickie Zhang, Caroline Almon, Michael K. Cooper, Martin S. Tallman	19
13	Abstract P5-19-24: Phase Ib/II study of LEE011 and BYL719 and letrozole in ER+, HER2– breast cancer: Safety, preliminary efficacy and molecular analysis 2015 ·Cancer Research ·Dejan Juric, Erika Hamilton, Laura García‐Estévez, Richard H. De Boer, Ingrid A. Mayer, Mario Campone, (unknown), Suraj G. Bhansali, Vickie Zhang, Becker Hewes, Pamela N. Münster	15
14	Ph IB study of LEE011 and BYL719 in combination with letrozole in ER+, HER2- breast cancer. 2014 ·Journal of Clinical Oncology ·Pamela N. Münster, Erika Hamilton, Laura García‐Estévez, Richard H. De Boer, Ingrid A. Mayer, Mario Campone, (unknown), Suraj G. Bhansali, Vickie Zhang, Becker Hewes, Dejan Juric	21
15	Kinetic modeling of hyperpolarized 13C1-pyruvate metabolism in normal rats and TRAMP mice 2009 ·Journal of Magnetic Resonance ·Matthew L. Zierhut, Yi‐Fen Yen, Albert P. Chen, Robert Bok, Mark J. Albers, Vickie Zhang, (unknown), Ilwoo Park, Daniel B. Vigneron, John Kurhanewicz, Ralph E. Hurd, Sarah J. Nelson	131
16	Feasibility of using hyperpolarized [1-13C]lactate as a substrate for in vivo metabolic 13C MRSI studies 2008 ·Magnetic Resonance Imaging ·Albert P. Chen, John Kurhanewicz, Robert Bok, Duan Xu, (unknown), Vickie Zhang, Sarah J. Nelson, Ralph E. Hurd, Daniel B. Vigneron	85

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact